Comparison
Alpha-GPC vs BPC-157
Side-by-side of Alpha-GPC and BPC-157. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Alpha-GPC
Alpha GPC supplement profile: 300 to 600 mg dosage, acetylcholine synthesis, attention and reaction-time evidence, side effects, and choline donor comparisons.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Effects at a glance
Alpha-GPC
- •Choline donor supplement, roughly 40% choline by weight; crosses blood-brain barrier efficiently
- •Replicated small gains in attention and reaction time at 300 to 600 mg in healthy adults
- •Standard prescription cognitive medication in much of Europe (Gliatilin) at 1,200 mg/day for vascular cognitive impairment
- •ASCOMALVA trial (n=210) showed cognitive preservation when added to donepezil over 24 months
- •Increases acute power output (~14%, single trial) and transient growth hormone secretion at 600 mg
- •TMAO production raises a contested cardiovascular concern at chronic high doses
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Side-by-side
| Attribute | Alpha-GPC | BPC-157 |
|---|---|---|
| Category | supplement | peptide |
| Also known as | L-Alpha glycerylphosphorylcholine, choline alfoscerate, GPC, alpha-glyceryl phosphorylcholine | Body Protection Compound-157, Pentadecapeptide BPC-157 |
| Half-life (hr) ↗ | 4 | 4 |
| Typical dose (mg) ↗ | 600 | 0.25 |
| Dosing frequency | 1 to 3 times daily | daily (anecdotal protocols) |
| Routes | oral | subcutaneous, intramuscular, oral |
| Onset (hr) | 1 | - |
| Peak (hr) | 2 | - |
| Molecular weight | 257.22 | - |
| Molecular formula | C8H20NO6P | C62H98N16O22 |
| Mechanism | Hydrolyzed to free choline and glycerophosphate after absorption; choline supports acetylcholine and phosphatidylcholine synthesis in CNS. | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. |
| Legal status | Dietary supplement (US); prescription medication in much of Europe | Not FDA approved; research-use-only grey market; banned by WADA (2022) |
| WADA status | allowed | banned |
| DEA / Rx | OTC supplement | Not FDA approved; not scheduled; research-chemical status |
| Pregnancy | Insufficient data; choline generally recommended in pregnancy | Insufficient data |
| CAS | 28319-77-9 | 137525-51-0 |
| PubChem CID | 71920 | 9941957 |
| Wikidata | Q411478 | Q4835418 |
Safety profile
Alpha-GPC
Common side effects
- mild GI upset
- headache
- dizziness
- occasional insomnia with evening dosing
Contraindications
- established cardiovascular disease (TMAO concern)
- concurrent strong anticholinergic therapy
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors (donepezil): additive cholinergic effect, basis for ASCOMALVA protocol(minor)
- scopolamine: partial counteraction of anticholinergic effect(minor)
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Which Should You Take?
Alpha-GPC comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Alpha-GPC.
- → If your priority is athletic performance, pick Alpha-GPC.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
Edge case: If you want to avoid research-only / gray-market sourcing, Alpha-GPC is the more accessible choice.
Default choice: Alpha-GPC. Lower friction to source, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Alpha-GPC and BPC-157?
Alpha-GPC and BPC-157 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Alpha-GPC or BPC-157?
Alpha-GPC half-life is 4 hours; BPC-157 half-life is 4 hours.
Can you stack Alpha-GPC with BPC-157?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper